Role of interleukin-8 in onset of the immune response in intravesical BCG therapy for superficial bladder cancer

In intravesical therapy for superficial bladder carcinoma urothelial cells may, through the production of cytokines, contribute to the bacillus Calmette-Guerin (BCG)-induced local immunological reaction and associated antitumor efficacy. The aim of this study was to investigate such a role for the n...

Full description

Saved in:
Bibliographic Details
Published in:Urolithiasis 1997, Vol.25 (1), p.31-34
Main Authors: de Boer, E C, Somogyi, L, de Ruiter, G J, de Reijke, T M, Kurth, K H, Schamhart, D H
Format: Article
Language:English
Subjects:
Administration, Intravesical
BCG Vaccine - administration & dosage
BCG Vaccine - therapeutic use
Bladder cancer
Carcinoma, Transitional Cell - therapy
Carcinoma, Transitional Cell - urine
Humans
Interleukin-2 - urine
Interleukin-6 - urine
Interleukin-8 - chemistry
Interleukin-8 - physiology
Interleukin-8 - urine
Medical research
Prognosis
Time Factors
Urinary Bladder Neoplasms - therapy
Urinary Bladder Neoplasms - urine
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In intravesical therapy for superficial bladder carcinoma urothelial cells may, through the production of cytokines, contribute to the bacillus Calmette-Guerin (BCG)-induced local immunological reaction and associated antitumor efficacy. The aim of this study was to investigate such a role for the neutrophil-attracting cytokine interleukin-8 (IL-8). The appearance of IL-8 in patients urine after BCG therapy was compared with BCG-induced IL-6 and IL-2 and the stability of IL-8 in urine was tested. Compared to IL-6 and IL-2, a rapid induction of IL-8 was observed, occurring after the first BCG instillation. Urinary IL-8 was highly stable, even after 24 h incubation at 37 degrees C. The IL-8 concentration after the first instillation seemed to be associated with subsequent development of an immune response. Consequently, IL-8 seems an attractive candidate for investigation of its prognostic value for a clinical response to BCG therapy.
ISSN:0300-5623
2194-7228
1434-0879
2194-7236
DOI:10.1007/bf00941903